


Zoniporide hydrochloride

Cat. No.:	HY-105064B
CAS No.:	241800-97-5
Molecular Formula:	C ₁₇ H ₁₇ ClN ₆ O
Molecular Weight:	356.81
Target:	Na ⁺ /H ⁺ Exchanger (NHE)
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Zoniporide (CP-597396) hydrochloride is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride inhibits human NHE-1 (IC ₅₀ =14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC ₅₀ =59 nM) ^{[1][2]} .																
IC₅₀ & Target	IC ₅₀ : 14 nM (NHE-1) ^[1]																
In Vivo	<p>Zoniporide (0.25-4 mg/kg; i.v.; every hour for 2 hours) elicits a dose-dependent reduction in infarct size (ED₅₀=0.45 mg/kg/h) in open chest anesthetized rabbits^[1].</p> <p>Zoniporide exhibits moderate plasma protein binding, has a t_{1/2} of 1.5 hours in monkeys, and has one major active metabolite^[1].</p> <p>Zoniporide treatment shows the AUC_{0-∞} and t_{1/2} are 0.07 µg h/mL and 0.5 hours, respectively^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Rabbit^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.25, 1, 4 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Every hour for 2 hours; intravenous injection</td> </tr> <tr> <td>Result:</td> <td>Elicited a significant dose-dependent reduction in infarct size in the anesthetized rabbit. The ED₅₀ was 0.45 mg/kg/h.</td> </tr> <tr> <td>Animal Model:</td> <td>Rat^[2]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection(Pharmacokinetic Analysis)</td> </tr> <tr> <td>Result:</td> <td>The AUC_{0-∞} and t_{1/2} were 0.07 µg h/mL and 0.5 hours, respectively.</td> </tr> </table>	Animal Model:	Rabbit ^[1]	Dosage:	0.25, 1, 4 mg/kg	Administration:	Every hour for 2 hours; intravenous injection	Result:	Elicited a significant dose-dependent reduction in infarct size in the anesthetized rabbit. The ED ₅₀ was 0.45 mg/kg/h.	Animal Model:	Rat ^[2]	Dosage:	1 mg/kg	Administration:	Intravenous injection(Pharmacokinetic Analysis)	Result:	The AUC _{0-∞} and t _{1/2} were 0.07 µg h/mL and 0.5 hours, respectively.
Animal Model:	Rabbit ^[1]																
Dosage:	0.25, 1, 4 mg/kg																
Administration:	Every hour for 2 hours; intravenous injection																
Result:	Elicited a significant dose-dependent reduction in infarct size in the anesthetized rabbit. The ED ₅₀ was 0.45 mg/kg/h.																
Animal Model:	Rat ^[2]																
Dosage:	1 mg/kg																
Administration:	Intravenous injection(Pharmacokinetic Analysis)																
Result:	The AUC _{0-∞} and t _{1/2} were 0.07 µg h/mL and 0.5 hours, respectively.																

CUSTOMER VALIDATION

-
- J Biol Chem. 2021 Sep 3;101166.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Tracey WR, et al. Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32.
- [2]. Guzman-Perez A, et al. Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg Med Chem Lett. 2001 Mar 26;11(6):803-7.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA